Oxiconazole|CAS 64211-46-7|DC Chemicals

Cas No.:	64211-46-7
Chemical Name:	(Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine;nitric acid
Synonyms:	Oxiconazole, Oxistat, Oxizole, Fonx, Myfungar; Ro 13-8996; Ro-13-8996; Ro13-8996; Sgd 301-76; ST 813; ST-813; ST813;
SMILES:	C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl.[N+](=O)(O)[O-]
Formula:	C₁₈H₁₄Cl₄N₄O₄
M.Wt:	492.1402
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Oxiconazole nitrate is a broad spectrum antifungal which can inhibit the growth of T. tonsurans and T. rubrum with MIC90s of 0.25 and 0.5 μg/mL, respectively.
Target:	MIC90: 0.25 μg/mL (T. tonsurans), 0.5 μg/mL (T. rubrum)[1]
In Vivo:	The baseline distortion product otoacoustic emission (DPOAE) results of the right ears of all animals tested are normal. Animals in groups I, II, IV and V show no statistically significant change in the DPOAE amplitudes. The rats in the gentamicingroup show a significant decrease[2].
In Vitro:	Oxiconazole nitrate is the more active compound in tests with T. tonsurans and T. rubrum. Twelve isolates are inhibited by 0.063 μg/mL of oxiconazole; corresponding econazole MICs range from 0.063 (three isolates) to 8 (two isolates) μg/mL. Three isolates have oxiconazole MICs of 16 or 32 μg/mL[1].
Cell Assay:	A total of 121 isolates of pathogenic fungi are tested. The three drugs (including Oxiconazole nitrate) are serially diluted in sterile saline. For each test plate, 2 mL of a solution of drug in sterile saline is added to an 18 mL blank of molten agar medium at 50°C and mixed well; the resulting mixtures are then poured into the plates and allowed to solidify. The resulting drug dilution sequences range from 128 to 0.063 μg/mL. Control plates are prepared in a similar manner using 2 mL blanks of sterile saline. The plates are then inoculated using a replicator. Incubation is at 30°C for a minimum of 96 hr. The Minimal Inhibitory Concentration (MIC) is defined as the lowest concentration of drug producing complete inhibition of growth[1]
Animal Administration:	Fifty adult rats are divided into 5 groups consisting of 10 animals each. Over 14 days, the rats in group I receive 0.1 mL of Oxiconazole nitrate-containing solution drops, group II receives 4% boric acid solution in alcohol drops, and groups III and IV receive gentamicin (40 mg/mL) and saline solutions, respectively. Group V receives no medication. Each solution used is given twice a day[2].
References:	[1]. Shadomy S, et al. Further in vitro studies with oxiconazole nitrate. Diagn Microbiol Infect Dis. 1988 Apr;9(4):231-7. [2]. Özdemir S, et al. Effects of topical oxiconazole and boric acid in alcohol solutions to rat inner ears. Otolaryngol Head Neck Surg. 2013 Jun;148(6):1023-7.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79609	NCGC00685960	NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC77831	Vicadrostat	Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813	Zeltociclib	Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77714	S3226	S3226 is an inhibitor for Na+/H+ exchange subtype 3 (NHE3) with an IC50 of 0.2 µmol/L in rat NHE3 transfected fibroblasts. S3226 exhibits protective activity in rat ischemia-induced acute renal failure models.
DC77387	AUR1545	AUR1545 is a selective degrader of KAT2A and KAT2B. AUR1545 can be used in the cancer research, including studies on AML (Acute myeloid leukemia), SCLC (Small-cell carcinoma), and NEPC (Neuroendocrine Prostate Cancer).
DC77822	JNJ-77242113 (Icotrokinr)	Icotrokinra (JNJ-77242113, JNJ-2113, PN-235) is an orally available and selective antagonist of the IL-23 receptor. It also inhibits IL-23–induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM and suppresses IL-23–induced IFN-γ production in NK cells with an IC50 of 18.4 pM. It also exhibits anti-inflammatory activity in a TNBS-induced colitis model in rats and holds potential for studying psoriasis, psoriatic arthritis, and inflammatory bowel disease.
DC77088	T025	T025 is as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs) with an IC50s of 0.93 nM, 1 nM, 14 nM, 1.5 nM for CLK1, CLK2, CLK3, DYRK1B respectively. It exhibits anti‐tumor efficacy and can be used in MYC‐driven cancer research.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.